We are international
Donate
• videos TEXT SIZE   

ASH 2007 WEBCAST

We are pleased to present these overviews of the 49th Annual American Society of Hematology Meeting (ASH) that was held in Atlanta, Georgia from December 8-11, 2007.

ASH 2007
previous     next      view all

New Agents
Dr. Orlowski - Safety and Antitumor Efficacy of the Proteasome Inhibitor Carfilzomib (PR-171) Dosed for Five Consecutive Days in Hematologic Malignancies: Phase 1 Results
Robert Z. Orlowski, MD
MD Anderson Cancer Center
Houston, Texas

Dr. Ocio - Antimyeloma Efficacy of Plitidepsin (Aplidin): From Bench to the Bedside
Enrique M. Ocio, MD
Hospital Universitario de Salamanca
Salamanca, Spain

Dr. Richardson - An Overview of Studies of the New Agent Perifosine (KRX-0401) Alone and in Combination for Patients with Relapsed/Refractory Multiple Myeloma
Paul Richardson, MD
Jerome Lipper Myeloma Center
Dana Farber Cancer Institute
Boston, MA
Member, IMF Board of Scientific Advisors

Dr. Richardson - Final Results of a Phase I Trial of Oral Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) in Patients with Advanced Multiple Myeloma
Paul Richardson, MD
Jerome Lipper Myeloma Center
Dana Farber Cancer Institute
Boston, MA
Member, IMF Board of Scientific Advisors

Dr. Ocio - Triple Combinations of the HDAC Inhibitor Panobinostat (LBH589) + Dexamethasone with Either Lenalidomide or Bortezomib Are Highly Effective in a Multiple Myeloma Mouse Model
Enrique M. Ocio, MD
Hospital Universitario de Salamanca
Salamanca, Spain

Dr. Dispenzieri - Pre-Clinical Data and Preliminary Patient Results of Intravenous MV-NIS To Treat Relapsed, Refractory Multiple Myeloma
Angela Dispenzieri, MD
Mayo Clinic
Rochester, Minnesota

Dr. Davies - Aminopeptidase Inhibition as a Targeted Treatment Strategy in Myeloma
Faith E. Davies, MD
The Royal Marsden NHS Foundation Trust
Sutton, Surrey, UK
Member, IMF Board of Scientific Advisors

Dr. Zonder - Phase I Trial of HuLuc63 in Multiple Myeloma
Jeffrey A. Zonder, MD
Karmanos Cancer Institute
Detroit, Michigan

Dr. Aggarwal: Curcumin downregulates NF-kB and related genes in patients with multiple myeloma: Results of a phase 1/2 study
Bahrat Aggarwal, PhD
MD Anderson Cancer Center
Houston, Texas

Transplantation
Dr. Harousseau - VELCADE/Dexamethasone (Vel/D) Versus VAD as Induction Treatment Prior to Autologous Stem Cell Transplantion (ASCT) in Newly Diagnosed Multiple Myeloma (MM): Updated Results of the IFM 2005/01 Trial
Jean Luc Harousseau, MD
Hematologie Clinique
CHU Hotel Dieu
Nantes, France
Member, IMF Board of Scientific Advisors

previous     next      view all